We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
EYDENZELT (Celltrion Healthcare Australia Pty Ltd)
Product name
EYDENZELT
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
Aflibercept
Registration type
EOI
Indication
EYDENZELT 2 mg (aflibercept) is indicated in adults for the treatment of:
- neovascular (wet) age-related macular degeneration (wet AMD)
- visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO)
- visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO)
- diabetic macular oedema (DME)